Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05289037 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 1,270
- Enrollment target
NCT05289037 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,270 participants.
The verdict
NCT05289037, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,270 participants
- Enrollment target
Study Summary
This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and will evaluate innate, cellular, and humoral immune responses to inform on how to shift the immune response to cover new variants as they emerge. A randomized open-label, non-placebo controlled, multi-site, multi-stage clinical trial in individuals, 18 years of age and older, who are in a stable state of health, has received a complete authorized/approved vaccine series (primary series + booster either with homologous or heterologous vaccine products) \>/ = 16 weeks prior to enrollment. Subjects will be stratified by i) age (18-64 years and = 65 years of age) (however arms 16 and 17 or stage 4 will only enroll participants between the ages of 18-49 years) and ii) history of confirmed prior SARS-CoV-2 infection, and randomly assigned to receive one of several variant vaccines. Enrollment will target a goal of approximately 45% of each of the variant vaccine arms to be in older adults (= 65 years of age) for stages 1, 2 and 3 and approximately 20% to have had confirmed COVID-19 for all 4 stages. The primary objective is to evaluate humoral immune responses of candidate SARS-CoV-2 variant vaccines, alone or in combination.
Interventions
- BIOLOGICAL BNT162b2
- DRUG AS03
- BIOLOGICAL BNT162b2 (B.1.1.529)
- BIOLOGICAL BNT162b2 (B.1.351)
- BIOLOGICAL BNT162b2 bivalent (wildtype and Omicron BA.1)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,270 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05289037
The ClinicalTrials.gov registry entry for NCT05289037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1,270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BNT162b2 is the first listed.
NCT05289037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05289037 about?
NCT05289037 is a clinical study titled "COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)". This phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and wil...
What is the current status of trial NCT05289037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,270 participants. The study started on 2022-03-30. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT05289037?
The interventions under investigation include: BNT162b2 (BIOLOGICAL), AS03 (DRUG), BNT162b2 (B.1.1.529) (BIOLOGICAL), BNT162b2 (B.1.351) (BIOLOGICAL), BNT162b2 bivalent (wildtype and Omicron BA.1) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05289037?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.